Compare peptides side-by-side
Pick any two peptides to compare their evidence quality, FDA approval status, research scores, risks, and indications. All data sourced from the SmartPeptide library.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
GHK-Cu
Copper tripeptide studied in dermatology for skin remodeling and wound contexts. Topical formulations are widely used in cosmetics.
Full pageTopical GHK-Cu has dermatology RCTs supporting effects on collagen, skin barrier, and post-procedure recovery. Reasonable mechanistic data for fibroblast and keratinocyte effects.
Injectable use in humans is largely unproven. Hair-loss and systemic anti-aging claims need larger trials.
Topical use is generally well tolerated; injectable use lacks robust safety data.
Skin irritation in sensitive users.
Argireline (Acetyl Hexapeptide-8)
Synthetic hexapeptide (Glu-Glu-Met-Gln-Arg-Arg) marketed as a topical 'botox alternative.' Theoretically interferes with SNARE complex formation, reducing neurotransmitter release at neuromuscular junctions. Topical formulations are widely sold in cosmetics. Effect size is modest at best in published trials.
Full pageSmall topical trials show measurable but modest reduction in wrinkle depth and frequency with 10% Argireline formulations over 4-8 weeks. Effect size is far smaller than botulinum toxin injection. Skin penetration is limited — most of the topical dose doesn't reach target.
Optimal formulation, delivery enhancement (e.g. liposomal), and combination with other topical actives. Injectable Argireline is NOT a thing — only topical.
Topical use is generally low-risk. Skin irritation possible. Theoretical concerns about systemic neuromuscular effects from topical absorption are unsupported by data — Argireline penetrates poorly.
Mild skin irritation, redness. Most users tolerate topical formulations well.